Fortem Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Fortem Financial Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-819	Closed	-$591K	–	161
2022 Q4	$591K	Hold	819	–	–	0.35%	87
2022 Q3	$564K	Sell	819 -160	-16%	-$101K	0.39%	79
2022 Q2	$579K	Sell	979 -3,702	-79%	-$2.41M	0.38%	86
2022 Q1	$3.27M	Buy	4,681 +800	+21%	+$506K	1.43%	14
2021 Q4	$2.45M	Buy	3,881 +42	+1%	+$25.8K	1.12%	28
2021 Q3	$2.32M	Buy	3,839 +106	+3%	+$65.8K	1.18%	24
2021 Q2	$2.08M	Buy	3,733 +1,296	+53%	+$657K	1.06%	28
2021 Q1	$1.15M	Buy	2,437 +62	+3%	+$30.2K	0.67%	58
2020 Q4	$1.15M	Sell	2,375 -124	-5%	-$66.9K	0.69%	47
2020 Q3	$1.4M	Buy	+2,499	New	+$1.52M	1.01%	34

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fortem Financial Group's REGN Position: Q1 2023 in Review

Fortem Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 819 shares — an estimated $591K sold.

Fortem Financial Group first reported a position in REGN in Q3 2020 and held it in 10 quarters. The position peaked at $3.27M in Q1 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Fortem Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Fortem Financial Group sold 819 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $591K.
Fortem Financial Group first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 10 quarters.
Fortem Financial Group's Regeneron Pharmaceuticals position peaked at $3.27M in Q1 2022.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Fortem Financial Group's 13F filing for Q1 2023, filed 21 Apr 2023.